Global efficacy and clinical application of androgen receptor inhibitors in metastatic prostate cancer

Affiliations

Free article

Comment

Ulka Vaishampayan. Chin Clin Oncol. 2023 Dec.

Free article

. 2023 Dec;12(6):61.

doi: 10.21037/cco-23-59. Epub 2023 Sep 6.

¹ Department of Medicine/Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.

No abstract available

Keywords: Androgen receptor inhibitors (ARIs); apalutamide; darolutamide; enzalutamide; rezvilutamide.

Comment on

Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial.
Gu W, Han W, Luo H, Zhou F, He D, Ma L, Guo H, Liang C, Chong T, Jiang J, Chen Z, Wang Y, Zou Q, Tian Y, Xiao J, Huang J, Zhu S, Dong Q, Zhang X, Li H, Yang X, Chen C, Li J, Jin C, Zhang X, Ye D; CHART Investigators. Gu W, et al. Lancet Oncol. 2022 Oct;23(10):1249-1260. doi: 10.1016/S1470-2045(22)00507-1. Epub 2022 Sep 5. Lancet Oncol. 2022. PMID: 36075260 Clinical Trial.